Programme Thesis
The Concours d'innovation i-Lab is a French national competition that funds early-stage, deep-tech startups with high innovation potential, aiming to accelerate the creation of innovative businesses based on research results. It exists to bridge the gap between laboratory proof-of-concept and commercial venture, providing both financial support and visibility to laureates.
Selection Criteria
- Innovation and technological breakthrough: degree of novelty and differentiation from existing solutions
- Market potential and economic viability: clarity of target market, business model, and growth prospects
- Quality of the team: expertise, complementarity, and commitment of founders
- Technical and scientific feasibility: maturity of the proof-of-concept and credibility of the development plan
- Intellectual property strategy: existence of patents or clear IP protection plan
- Social and environmental impact: contribution to societal challenges (e.g., health, sustainability)
- Project maturity: readiness level (TRL 3-6 typically), clarity of milestones and budget
Past Winners / Cohort Profiles
Past winners include a wide range of deep-tech startups from biotech, medtech, AI, and clean energy sectors. Typical archetypes are spin-offs from French public research labs (CNRS, INSERM, CEA) or early-stage startups with a strong patent portfolio and a clear industrial partner. Named examples are not available from the provided URL, but the programme historically awards ~50-70 projects per edition, with amounts varying by track (e.g., €30k-€600k).
Ideal Candidate Fingerprint
The ideal applicant is a French-based or EU-based team (at least one founder in France) with a disruptive technology validated at TRL 3-5, a provisional patent or clear IP strategy, and a credible path to market within 2-3 years. The team should combine scientific excellence with entrepreneurial drive, and the project should address a significant unmet need in a large or fast-growing market.
Recommended Framing
Eniola should position his CCT model and IMPRINT/TOPOLOGIX platforms as a breakthrough in addiction-liability screening and drug safety, leveraging AI and topological data analysis to solve a critical global health challenge. He must emphasize the provisional patent, endorsements from leading neuroscientists (Berridge, Gershman, Daw), and the validated proof-of-concept (85.8% reduction in encoding probability) to demonstrate technical feasibility. However, he needs to address the France/EU location requirement—if he cannot establish a French co-founder or legal entity, this programme may be ineligible; otherwise, he should frame his work as a potential French-based spin-off with a local collaborator.
Watch Out
The programme requires the applicant or at least one co-founder to be based in France or the EU, and the project must be developed in France. Eniola is currently in Lagos, Nigeria, with no stated French/EU affiliation, which is a critical eligibility barrier. Additionally, the programme typically funds startups rather than individual researchers, so a clear business plan and team structure are essential. Without a French co-founder or host institution, this application is likely ineligible.